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Abstract
Background: To evaluate the experience of induction chemotherapy followed by concurrent chemoradiationwith
helical tomotherapy (HT) for nasopharyngeal carcinoma (NPC).
Methods: Between August 2006 and December 2009, 28 patients with pathological proven nonmetastatic NPC
were enrolled. All patients were staged as IIB-IVB. Patients were first treated with 2 to 3 cycles of induction
chemotherapy with EP-HDFL (Epirubicin, Cisplatin, 5-FU, and Leucovorin). After induction chemotherapy, weekly
based PFL was administered concurrent with HT. Radiation consisted of 70 Gy to the planning target volumes of
the primary tumor plus any positive nodal disease using 2 Gy per fraction.
Results: After completion of induction chemotherapy, the response rates for primary and nodal disease were
96.4% and 80.8%, respectively. With a median follow-up after 33 months (Range, 13-53 months), there have been 2
primary and 1 nodal relapse after completion of radiotherapy. The estimated 3-year progression-free rates for local,
regional, locoregional and distant metastasis survival rate were 92.4%, 95.7%, 88.4%, and 78.0%, respectively. The
estimated 3-year overall survival was 83.5%. Acute grade 3, 4 toxicities for xerostomia and dermatitis were only
3.6% and 10.7%, respectively.
Conclusion: HT for locoregionally advanced NPC is feasible and effective in regard to locoregional control with
high compliance, even after neoadjuvant chemotherapy. None of out-field or marginal failure noted in the current
study confirms the potential benefits of treating NPC patients by image-guided radiation modality. A long-term
follow-up study is needed to confirm these preliminary findings.
Keywords: Concurrent chemoradiation, Intensity-modulated radiotherapy, Helical tomotherapy, Nasopharyngeal
carcinoma
Background
Locally advanced NPC patients present with poor prog-
nosis. This has led to increasing interest in exploring
the use of chemotherapy. Recently, meta-analysis has
confirmed the superiority of concurrent chemoradiation
(CCRT) over radiotherapy (RT) alone in terms of survi-
val or locoregional control among patients with locally
advanced NPC [1-3]. However, the optimal regimen and
scheduling remains to be determined and efforts to
improve the increased toxicities are still unremitting.
With the improvement of RT techniques, such as
intensity-modulated radiotherapy (IMRT) or image-
guided radiotherapy (IGRT), radiation oncologists have
the ability to deliver tumoricidal doses to the target
while maintaining tolerable doses to critical organs.
Recently, several non-randomized studies have demon-
strated impressive tumor control and survival using
IMRT in NPC. Moreover, the predominant failure
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any medium, provided the original work is properly cited.pattern is now distant failure rather than local failure
[4]. To conquer distant metastasis, adding induction
chemotherapy or adjuvant chemotherapy to concurrent
chemoradiation is still an attractive approach that needs
to be clarified.
Helical tomotherapy (HT), an innovative image-guided
IMRT device, can perform daily CT image registration
before treatment and deliver 51-angled rotational IMRT.
Our institute started the first HT treatment using
Tomotherapy Hi-Art systems (Tomotherapy, Madison,
WI) in December 2006. Using HT, we have previously
reported encouraging experiences for oropharyngeal [5],
postoperative treatment of high-risk oral cavity cancer
[6] and cervical cancer [7]. In comparison with conven-
tional IMRT, the HT results have demonstrated better
dosimetry coverage and highly conformal dose distribu-
tions to the targets and the impressive ability to simulta-
neously spare critical organs. In the treatment of
nasopharyngeal carcinoma, tomotherapy plans were
superior to IMRT plans in conformity and homogeneity
of planning target volume (PTV) and the sparing of the
critical organs at risk (OARs) [8].
We herein report our preliminary experience of con-
current helical tomotherapy plus chemotherapy follow-
ing induction chemotherapy for locally advanced NPC,
with special focus on response rate, acute treatment-
related sequelae and failure pattern and locoregional
control.
Methods
Patient Characteristics
Between August 2006 and December 2009, 28 patients
with pathological proven NPC were enrolled in this ret-
rospective analysis. All of the patients were diagnosed as
non-metastatic NPC in the cancer work-up initially.
Approval for the study was obtained from the Institu-
tional Review Board of Far Eastern Memorial Hospital
(FEMH No. 100050-E). The clinical characteristics are
detailed in Table 1. There were 22 men and 6 women
with a median age of 47.5 years. Most patients (85.7%)
had pathology of WHO type III (undifferentiated carci-
noma). Patients were staged according to the 2002
American Joint Committee on Cancer (AJCC) staging
system. All patients were staged as having locally
advanced disease (stage IIB-IVB). Table 2 detailed the
TNM distribution of the patients.
Staging workups included complete histories and phy-
sical examinations, fiberoptic endoscopic evaluation,
complete blood counts, liver and renal function tests,
chest X-rays, abdominal ultrasound, magnetic resonance
imaging (MRI) scans of the head and neck region, bone
scan and dental evaluation. CT scans of the chest and
abdomen were obtained whenever possible before the
beginning of treatment if distant metastasis was
suspected by abnormal finding in chest x-ray or abdom-
inal ultrasound.
Chemotherapy
All patients were treated with induction chemotherapy
followed by CCRT with HT. Induction chemotherapy
regimens, EP-HDFL, consisted of Epirubicin 40 mg/m
2,
30 minutes infusion, followed by Cisplatin 60 mg/m
2,5 -
FU 2000 mg/m
2, and Leucovorin 300 mg/m
2,2 4h o u r s
infusion on day 1, and 5-FU 2000 mg/m
2,a n dL e u c o v -
orin 300 mg/m
2, 24 hours infusion on day 8 and 15,
repeated every 4 weeks. Three cycles were planned
unless severe side effects occurred. Chemotherapy dur-
ing the CCRT phase, PFL, consisted of Cisplatin 30 mg/
m
2, 5-FU 450 mg/m
2 as bolus, and Leucovorin 30 mg/
m
2,o naw e e k l yb a s i s .C u r a t i ve radiotherapy began
within 3 weeks after completion of the last cycle of
induction chemotherapy.
Table 1 Characteristics of 28 patients
Variable number percent
Gender
Male 22 78.6%
Female 6 21.4%
Stage (AJCC, 2002)
IIB 3 10.7%
III 15 53.6%
IVA/B 10 35.7%
T stage
T1-T2 11 39.3%
T3-T4 17 60.7%
N stage*
N0-N1 8 28.6%
N2-N3 20 71.4%
Field-dose arrangement
SIB 24 85.7%
Conventional shrinking field 4 14.3%
Pathology
WHO I & II 4 14.3%
WHO III 24 85.7%
Table 2 Dose-volumetric statistics for target volumes
Parameters Mean (range)
PTV70 PTV63
Volume (cc) 253.8 (61.7-776.1) 528.8 (175.8-1213.2)
Mean dose (Gy) 71.9 (70.1-75.3) 64.3 (54.2-68.8)
Maximum dose (Gy) 74.4 (70.3-79.7) 69.4 (54.6-76.1)
Minimum dose (Gy) 60.1 (44.9-69.7) 47.4 (26.8-57.6)
D95 (Gy) 70.1 (68.8-72.0) 61.4 (53.9-67.0)
V97 (%) 98.3 (95.3-100.0) 97.8 (94.6-100.0)
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Immobilization and Contouring
Patients were immobilized using perforated Type-S ther-
moplastic head frames (MT-CFHN-C; Civco Medical
Solutions, Kalona, IA) for head and shoulder immobili-
zation after induction chemotherapy completed. The
head frames would be corrected after a significant neck
burden reduction during CCRT. A volumetric contrast
enhanced CT image in serial 3 mm slices was acquired
for treatment planning.
Target and Normal Tissue Volume Delineation and
Constraints
Target objects and normal structures were outlined slice
by slice on the treatment planning CT. On several occa-
sions, RT-planning images were fused with diagnostic
MRI to improve target delineation.
The gross tumor volume (GTV) encompassed the
gross extent of the primary tumor and involved neck
nodes shown by imaging before induction chemother-
apy as well as physical examination. Whenever possi-
ble, MRI scan done before induction chemotherapy
(24/28) was used in addition to the CT scan to deline-
ate the GTV with the assistance of a neuroradiologist.
A GTV node was outlined to have a nodal size larger
than 10 mm in the short-axis diameter or the presence
of central lucency on CT or MRI images. The clinical
target volume of 70 Gy (CTV70) included the GTV
with an additional 10 mm margin and GTV of node
with an expansion of 5 mm, respectively. The clinical
target volume of 63 Gy (CTV63) was designed to
include areas at risk for microscopic involvement, as
well as the entire nasopharynx, retropharyngeal nodal
regions, skull base, clivus, pterygoid fossae, paraphar-
yngeal space, sphenoid sinus, the posterior one third of
the nasal cavity/maxillary sinuses that includes the
pterygopalatine fossae, and levels I through V nodal
regions. Level II nodes were contoured bilaterally to
the base of skull. The clinical target volume of 56 Gy
(CTV56) was designed for the low-risk subclinical dis-
ease area. To account for organ motion and patient
setup errors, all of the PTV70, PTV63 and PTV56
were defined as CTV plus a margin of 3 mm. For
patients treated with the whole-field SIB technique,
PTV70, PTV63 and PTV56 were delivered in the same
days and all were amenable to be completed in 35
fractions within 7 weeks.
Critical structures included the brainstem, spinal cord,
brain, lens, eyeballs, optic chiasma, optic nerve, inner
ear, oral cavity, mandible, parotid gland, larynx, and
lung. Optimization was performed using the following
criteria for dose constraints. The dose constraints for
OARs were as follows: (1) brainstem: maximum dose 50
Gy, (2) spinal cord: maximum dose 40 Gy, (3) optic
chiasm and optic nerve: maximum dose 45 Gy, (4)
mandible: maximum dose 70 Gy or 1 cm
3 or less for 70
Gy or more, (5) bilateral parotid glands: mean dose less
than 30 Gy, and median dose less than 26 Gy, and
whole parotid gland volume, with a dose less than 20
Gy, more than 20 cm
3, and (6) middle and inner ear:
mean dose less than 50 Gy. The planning OAR volume
(PRV) was set as the brain stem and spinal cord with 5-
mm margins in the axial plane. The PRVs of the
chiasma and optic nerve were set with 3-mm margins in
every direction.
Treatment Plan and Delivery
The field width, pitch, and modulation factor usually
used for treatment planning optimization were 2.5 cm,
0.32, and 3.0, respectively. Maximum importance was
given to target dose coverage. The constraints on dose
and penalty were adjusted accordingly during optimiza-
tion. All patients received daily megavoltage CT acquisi-
tions for setup verification.
Follow-up
T h er e s p o n s ec r i t e r i aw e r ea sf o l l o w s :ac o m p l e t e
response was defined as complete regression of all evi-
dence of disease; a partial response required a 50%
decrease of the summed products of the two largest per-
pendicular diameters of all measurable lesions, without
an increase in size of more than 25% in any lesion or
the appearance of new lesions; stable disease was
defined as no significant change or any change in tumor
size that was less than a partial response but not large
enough to be considered progressive disease; and pro-
gressive disease was defined as an increase of at least
25% in the size of measurable lesions or the appearance
of any new lesion. Response was assessed before the
initiation of radiotherapy and 3 months after completion
of the treatment, respectively.
The acute toxicity occurring within 90 days since the
beginning of RT was assessed weekly throughout the
treatment. The toxicities were defined and graded
according to the Common Terminology Criteria for
Adverse Events, version 3.0 [9].
Statistical methods
Descriptive statistics (mean, median, and proportions)
were calculated to characterize the patient, disease, and
treatment features, as well as toxicities after treatment.
The OS, PFS, LRPF, and DMF rates were estimated
using the Kaplan-Meier product-limit method [10].
Freedom from local progression was defined as the
absence of primary tumor upon physical examination
and radiographic examination (CT and MRI scan).
Durations were calculated from the date of pathologic
proof. Differences were considered significant at p <
0.05. MedCalc statistical software (version 11.2.1.0, Med-
Calc Software, Mariakerke, Belgium) was used for
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generating tables and graphs that summarize data.
Results
Dose-volume analysis
Dose-volume histograms statistics for the PTV and
organs at risk (OARs) are described in table 2 and 3,
respectively. The D95 in PTV70 ranged from 68.8 Gy
(98% of the prescription dose) to 72 Gy (100% of the
prescription dose). The V97 in PTV70 ranged from
97.3% to 100%. Mean doses to parotid glands were 33.7
Gy (25.90-43.49 Gy) for the right and 34.1 Gy (24.02-
48.72 Gy) for the left. The other OARs are summarized
in Table 3.
Response
Most patients (85.7%) were treated with Whole-field SIB
(simultaneous-integrated boost) HT techniques. The
median follow-up duration was 33 months (range: 13 to
53 months). Thirteen patients received 2 cycles of
induction chemotherapy due to severe nausea (1/28),
neutropenia (1/28), sepsis (1/28) and partial response
with unsatisfactory response judged by medical oncolo-
gist (10/28). The remaining underwent 3 cycles of che-
motherapy. Primary tumors had a higher response rate
to induction chemotherapy (96.4%) compared with
nodal disease (80.8%) which was evaluated by endoscopy
& CT or MR for all patients. The complete response
rates were 39% and 27% for the primary tumor and
neck node, respectively. (Table 4) No patients experi-
enced disease progression during chemotherapy. Also,
after remission via induction chemotherapy, there were
no patients who had primary or lymph node enlarge-
ment during the rest period before CCRT.
After induction chemotherapy, all patients also received
CCRT with HT and achieved complete or partial remis-
sion either in the primary site or gross neck nodes. The
median cycles for patients received chemotherapy during
RT were 4 cycles (range: 2-7 cycles). There were 4 (14.3%),
2 (7.1%) and 3 (10.7%) of patients received chemotherapy
during RT with 5, 6 and 7 cycles, respectively. The average
w e e k sf o rC C R Tw e r e7 . 8±1 . 1w k s( r a n g e :6 - 1 0w k s ) .
There were 7 (23.3%) and 2 (6.7%) patients completed the
CCRT course within 9 and 10 wks, respectively. The com-
plete response rate of the nodal area (80.8%) was inferior
to primary location (92.9%). After completion of the whole
treatment, small residual tumors were noted either at the
primary site or neck with 7.1% and 19.2% of patients,
respectively. These residual tumors all showed complete
regression upon follow-up after 3 months (Table 4).
Treatment outcome
The estimated 3-year progression-free (PF) rates for
local, regional, locoregional and DMF survival rate were
92.4%, 95.7%, 88.4%, and 78.0%, respectively. The 3-year
estimates of locoregional PF for patients with stage II-IV
disease were 100%, 92.9%, and 76.2%, respectively. The
3- year estimated OS was 83.5% (Figure 1). No patient
was lost as of follow-up. Three patients and 2 patients
died by distant failure and intercurrent disease (one of
chemotherapy related septic shock and the other died of
cardiac dysfunction probably related to the anthracy-
cline-chemotherapy of cardiac [11]), respectively.
Acute Toxicities
The median treatment period during CCRT was 54 days
(range: 42 to 73 days). No fatal toxicity related to the
Table 3 Dose-volumetric statistics for organs at risk
(OARs)
Organs Mean (range)
Spinal cord [Dmax(Gy)] 40.70 (29.20-53.84)
Brainstem [Dmax(Gy)] 50.15 (31.49-62.01)
Right Optic nerve [Dmax(Gy)] 46.08 (19.40-76.39)
Left Optic nerve [Dmax(Gy)] 43.75 (7.98-72.70)
Optic chiasm [Dmax(Gy)] 46.49 (25.50-73.06)
Right inner ear
Dmax (Gy) 59.40 (47.61-73.53)
Dmean (Gy) 41.87 (24.43-65.37)
Left inner ear
Dmax (Gy) 60.26 (40.87-74.55)
Dmean (Gy) 43.26 (23.01-70.41)
Right parotid gland
Dmean (Gy) 33.71 (25.90-43.49)
V30 Gy (%) 45.64 (29.30-60.00)
Left parotid gland
Dmean (Gy) 34.09 (24.02-48.72)
V30 Gy (%) 46.38 (27.10-78.39)
Table 4 Clinical response after induction chemotherapy
and 2 months after completion of CCRT
Response After Induction After
Concomitant
No. (%) Chemoradiation chemotherapy
Nasopharynx, by endoscopy & CT
or MR
SD 1/28(3.6%) 0/28(0.0%)
PR 16/28(57.1%) 2/28(7.1%)
CR 11/28(39.3%) 26/28(92.9%)
Neck node, by CT or MR
SD 5/26*(19.2%) 0/26(0.0%)
PR 14/26(53.8%) 5/26(19.2%)
CR 7/26(26.9%) 21/26(80.8%)
*Two patients were staged as T4N0, so 26 patients were available for nodal
evaluation.
Abbreviations:
SD: stable disease, PR: partial response, CR: complete response.
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tion chemotherapy, all but 3 patients had normal hemo-
gram (Table 5). During induction chemotherapy, grade
3 leukopenia occurred in 1 patient. No patients experi-
enced grade 3 anemia or grade 3 thrombocytopenia.
However, the low toxicities of induction chemotherapy
are probably due to the low doses of CDDP and
Epirubicin.
For CCRT with HT, 4 patients (14.3%) developed grade
3 leukopenia and 1 patient (3.6%) developed grade 3 ane-
mia during treatment. Acute nonhematological toxicities
related to radiotherapy, including xerostomia and dermati-
tis, were mostly mild (Table 6.) Only 1 patient had grade 3
xerostomia. Grade 3 or 4 dermatitis was noted in 2 and 1
patients, respectively. However, 13 patients (46.4%) suf-
fered from grade 3 mucositis. Other grade 3 reactions
such as dysphagia and weight loss were noted in 4 and 2
patients, respectively. Seven patients (25.0%) needed NG
feeding for nutritional supports.
Late Toxicities
For CCRT with HT, none of patients developed grade 3
toxicities related to radiotherapy, including xerostomia,
dysphagea, dry eyes, trismus and hearing loss. Most of
them are normal to grade 1 of toxicities. Only 4/28
patient had grade 2 xerostomia and 1/28 had grade 2
hearing loss.
Failure pattern
There were 89.3% (25/28) without locoregional failure.
The failure pattern disclosed as follows: local failure
only, 2 patients (7.1%); regional failure only, 1 patient
(3.6%); distant metastases only, 4 patients (14.3%); and
no local plus regional and/or distant failure.
One patient with initial stage IV disease (cT4N1M0)
failed locally at the ethmoid sinus 10 months post treat-
ment. After functional endoscopic sinus surgery and
adjuvant chemotherapy, the disease was well controlled.
(Figure 2A and 2B) Another patient with stage IV dis-
ease (cT4N3bM0) failed at the nasopharynx 14 months
after the treatment. She then underwent local irradiation
plus cetuximab and chemotherapy but died of septic
shock. (Figure 2C and 2D)
The only patient who failed for nodal disease with
initial stage III disease (cT3N2M0) suffered from left
upper neck relapse 16 months after completion of treat-
ment and then was successfully salvaged by neck dissec-
tion. (Figure 2E and 2F) No adjuvant treatment was
done since only one of 16 dissected nodes showed meta-
static lesion. No extracapsular extension or other patho-
logical risk factors were noted. The failure was in a
Figure 1 The actuarial overall survival rates at 3 years.
Table 5 Acute hematological toxicities in 28 patient after induction chemotherapy and concurrent chemoradiation
according to CTCAE v3.0
Item anemia leucopenia thrombocytopenia
Interval before IC CCRT before IC CCRT before IC CCRT
Grade
0 25(89.3%) 11(39.3%) 7(25.0%) 28(100.0%) 19(67.9%) 8(29.6%) 27(96.4%) 17(60.7%) 13(46.4%)
1 1(3.6%) 13(46.4%) 10(35.7%) 0 5(17.9%) 4(14.8%) 1(3.6%) 11(39.3%) 10(35.7%)
2 1(3.6%) 4(14.3%) 10(35.7%) 0 3(10.7%) 12(44.4%) 0 0 5(17.9%)
3 0 0 1(3.6%) 0 1(3.6%) 4(11.1%) 0 0 0
4 1(3.6%) 0 0 0 0 0 0 0 0
Abbreviations:
CTCAE v3.0: the Common Terminology Criteria for Adverse Events, version 3.0. IC: induction chemotherapy (IC); CCRT: concurrent chemoradiation.
Table 6 Acute radiation-related toxicities according to
CTCAE v3.0
Acute toxicities
Grade xerostomia mucositis dysphagia dermatitis weight loss
0 0 0 1(3.60%) 0 2 (7.1%)
1 13(46.4%) 4(14.3%) 8(28.6%) 17(60.7%) 12(42.9%)
2 14(50.0%) 11(39.8%) 15(53.6%) 8(28.6%) 12(42.9%)
3 1(3.6%) 13(46.4%) 4(14.3%) 2(7.1%) 2(7.1%)
4 0 0 0 1(3.6%) 0
Abbreviations:
CTCAE v3.0: the Common Terminology Criteria for Adverse Events, version 3.0.
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margins or out of RT fields. The local and regional con-
trols after salvage treatment were 96.4% and 100%,
respectively.
Four patients developed distant metastases over the
bone, liver, liver plus bone, and lung at the 6th, 7th,
10th and 40th month after completion of treatment. All
of these 4 patients had N2 disease (stage III and IV).
T h ea v e r a g er e l a p s et i m ew a s8m o n t h s .T h r e eo ft h e m
were died of disease progression and only one patient
with liver metastases is still alive with disease and now
under systemic treatment. We observed no parotid or
dermal failure.
Discussion
Impressive clinical data of NPC treated by IMRT have
been reported in recent years. In one study, the 4-year
local progression-free and regional progression-free
rates for loco-regional advanced NPC patients were
97% and 98%, respectively [12]. Recent results from
Hong Kong and the Memorial Sloan-Kettering cancer
center have also shown similar findings [13-15]. How-
ever, with integration of aggressive concurrent chemor-
adiotherapy schedules, the changing failure pattern has
been noted in several publications [12,16,17] and the
distant metastases rates, nevertheless, can be as high as
30% [4].
To conquer the problem of distant metastases, adding
neoadjuvant chemotherapy or adjuvant chemotherapy
with concurrent chemoradiation is still an attractive
approach that needs to be clarified, although post
experience is very sparse. A study conducted in Hong
Kong [18] reported that 24/25 locally advanced NPC
patients achieved partial remissions after induction che-
motherapy. Additionally, the 3-year local-PF, regional-
PF, and DM-PF survival rates were 89.6%, 87.2%, and
80.4%, respectively. China has report the largest series of
concurrent chemotherapy and IMRT data, with 323
locoregionally advanced NPC patients with neoadjuvant
or adjuvant chemotherapy [19]. The overall 3-year local-
PF, regional-PF, DM-PF, and overall survival rates were
93.6%, 93.3%, 86.6%, and 87.2%, respectively. A study in
Japan demonstrated the first experience of HT plus che-
motherapy for 20 patients with a limited observation
period. However, 18 patients who underwent che-
motherapy with NDP (cis-diammineglycolatoplatinum,
Nedaplatin) and 5FU were in alternating settings. Dur-
ing the alternating chemoradiotherapy and with a med-
ian FU of 10.9 months, one patient failed in the regional
node and another one failed in the liver. The 10-month
OS was 95% [20]. In the current study, induction che-
motherapy and CCRT with HT were well tolerated.
During neoadjuvant chemotherapy, only one patient
occurred grade 3 leukopenia. No patients experienced
grade 3 anemia or thrombocytopenia. Four patients
developed grade 3 leukopenia and 1 patient developed
grade 3 anemia during the following CCRT with HT
treatment. The median treatment time for CCRT was
54 days. The estimated 3-year PF for local, regional, and
locoregional survival rates were 92.4%, 95.7%, and
88.4%, respectively. HT for locoregionally advanced
NPC was shown to be feasible and effective in regard to
locoregional control with high compliance, even after
neoadjuvant chemotherapy.
Even though nearly 90% of our patients had locally
advanced disease (stage III and IV), patients had excel-
lent locoregional control rates after HT plus
Figure 2 The comparison of original planning dose distribution
(red color area) and locoregional failure (red arrow). For patient
1. (A) In 2007/4, planning Dose distribution of 70 Gy (red color area)
at ethmoid sinus; (B) In 2008/1, MRI images show a local relapse.
For patient 2. (C) In 2008/11, planning dose distributions of 71.6 Gy
(red color area) at skull base; (D) In 2009/3, PET-CT images show a
at skull base, SUVmax = 6.4. For patient 3. (E) In 2008/7, planning
Dose distributions of 70 Gy (red color area) at neck lymph node
and lymphatic drainage; (F) In 2009/6, MRI images show a regional
lymph node relapse.
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7 relapsed patients in the current study, 4 patients pre-
sented distant metastases. The regiment of induction
chemotherapy in the current study was CDDP/Epirubi-
cin/5-FU/Leucovoren (60/40/2000/300 mg/m2). Com-
pared to the other studies, the doses of CDDP and
Epirubicin in the current study were lower than the
other studies [14,21,22]. The 3-year DMF survival rate
was 78%, suggesting that distant metastases are still the
major obstacle to be broken through. Moreover, present
regimens of chemotherapy are not effective enough in
preventing distant metastases and should be reevaluated.
Higher irradiation doses deliver high rates of locore-
gional control, progression-free survival for head and
neck cancer [23]. However, we may need to be con-
cerned about late complications if the dose is escalated
and the volume of tissues are exposed to high doses
[24]. On the other hand, if the volume of tissues
exposed to high doses is reduced with image-guided
IMRT, there is a possibility that treatment could achieve
higher locoregional control rate and the probability of
such complications could be reduced simultaneously. In
the current study, the locoregional failure of 3 patients
all belonged to in-field failure. The D95 in PTV70 ran-
g e df r o m6 8 . 8G yt o7 2G ya n dt h eV 9 7i nP T V 7 0r a n -
ged from 97.3% to 100%, respectively. (Table 2) None of
the out-field or marginal failures noted in the current
study showed 3 mm of PTV’s margin, confirming the
potential benefits of treating NPC patients with image-
guided radiation modality. This finding also suggests
that using 3 mm as the PTV margin in image-guided
radiation therapy settings is feasible. Additionally, lim-
ited grade 3 of xerostomia, dysphagia and dermatitis
were noted in the current setting (Table 6). Moreover,
most of patients are normal to grade 1 of late toxicities.
Only 4/28 patient had grade 2 xerostomia and 1/28 had
grade 2 hearing loss. With accurate image-guided mod-
ality, dose escalation with reduced increase of toxicity
for OARs becomes more reliable, providing relief for
locoregionally advanced NPC patients.
One patient died of cardiac dysfunction, and the pos-
sibility that the toxicity was related to epirubicin used in
induction chemotherapy should be considered. The
range of total dose for epirubicin that cause cardiac
toxicities is around 560-600 mg/m
2[11,25]. Bonneterre J,
et al [25] reported that there were 2/85 cases of conges-
tive heart failure observed after adjuvant treatment with
six cycles of fluorouracil 500 mg/m
2, epirubicin 100 mg/
m
2, and cyclophosphamide 500 mg/m
2 for breast cancer
patients in the 8 years follow up. Hasbini A, et al [11]
used mitomycin, 5-fluorouracil, epirubicin, and cisplatin
to treat recurrent and metastatic undifferentiated carci-
noma of nasopharyngeal and one 42-year-old patient
died of cardiac failure which was probably related to the
anthracycline-chemotherapy. In the current study, three
cycles of 40 mg/m
2 induction epirubicin was prescribed
and the total dose was 120 mg/m
2. Although, the total
dose of epirubicin is far from the doses that cause car-
diac toxicity.
Even though this innovative approach acquired
favorable outcomes with impressive locoregional con-
trol and survival result, several limitations need to be
addressed. First, our study was retrospective and was
carried with inherent biases usual to such a study
design. Second, our sample size was small. Thus, these
findings should be considered as preliminary and in
need of validation in a larger patient group. Third, the
study lacked in-house comparable results such as
tomotherapy versus conventional IMRT or current
regimen versus concurrent chemoradiation. Further-
more, the observation of long-term toxicities should be
reported in the future. The clinical benefit of modern
IGRT using tomotherapy, hence, could not be fully
determined. Due to these limitations, this combination
protocol must not be used in the daily practice of
treatment for locally advanced NPC.
Conclusions
In conclusion, this is the first report providing evidence
that HT for locoregionally advanced NPC is feasible and
effective in regard to locoregional control with high
compliance, even after neoadjuvant chemotherapy. No
out-field or marginal failure was noted in the current
study, confirming the potential benefits of treating NPC
patients with image-guided radiation modality. A long-
term follow-up study is needed to confirm these preli-
minary findings.
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